COLLEGEVILLE, Pa., June 26 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth , announced today the appointment of Andreas Krebs, 50, to President - Europe/Middle East/Africa and Canada, effective immediately. In this new role, Mr. Krebs will report to Joseph M. Mahady, President - Wyeth Pharmaceuticals, and Senior Vice President, Wyeth.
Mr. Krebs joined the Company in July 2003 as General Manager, Wyeth Germany, and since that time has worked to transform the German affiliate into one of the fastest growing companies in the market. He serves on the Board of the VFA (Germany’s trade organization for research companies) and is a member of the Board of Trustees in the Max Planck Institute for Molecular Biomedicine and the Paul Ehrlich Society for Chemotherapy.
Prior to joining Wyeth, Mr. Krebs was with Bayer for approximately 20 years, where he held a variety of pharmaceutical marketing and sales leadership positions in Europe, Latin America, Asia and Canada. He holds a degree in Commercial Management and Business Administration from the In-House Academy of Woelm Pharma, Eschwege, Germany.
Wyeth is one of the world’s largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company’s major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
CONTACT: Media, Douglas Petkus, +1-973-660-5218, or Investors, Justin
Victoria, +1-973-660-5340, both of Wyeth
Web site: http://www.wyeth.com/
